Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Purified CD4 T Lymphocyte Infusion Can Result in Graft-Versus-Leukemia Reactivity without Gvhd by Recognition of Broadly Expressed Minor Histocompatibility Antigens in HLA Class-II

P. van Balen, MD, C.A.M. van Bergen, I. Jedema, PhD, S.A.P. van Luxemburg-Heijs, J.C. Harskamp, H.M. van Egmond, S.A.J. Veld, M. Griffioen, PhD, W.A.F. Marijt, MD, PhD, C.J.M. Halkes, MD, PhD, J.H.F. Falkenburg, MD, PhD

Blood (2012) 120 (21): 4116.

https://doi.org/10.1182/blood.V120.21.4116.4116

Published: 2012

Journal Articles

Alemtuzumab Treatment Can Affect CD52 Positive As Well As CD52 Negative GPI-Deficient, Sezary Cells Allowing Long-Term Disease Control

C.J.M. Halkes, MD, PhD, I Jedema, PhD, H.M. van Egmond, L van der Fits, PhD, J.H.F. Falkenburg, MD, PhD, MH Vermeer, MD, PhD

Blood (2011) 118 (21): 2491.

https://doi.org/10.1182/blood.V118.21.2491.2491

Published: 2011

Journal Articles

In Vivo T Cell Depletion Using Rabbit Derived ATG Leads to An Increased EBV-PTLD Risk Due to An Induced Imbalance Between B and T Cell Recovery Which Is Not Seen After Horse Derived ATG or Alemtuzumab

C.J.M. Halkes, MD, PhD, J.H.F. Falkenburg, MD, PhD, H.M. van Egmond, J. Olde Wolbers, C.W.J. Starrenburg, P. van Balen, MD, M. van de Meent, P.A. von dem Borne, MD, PhD, W.A.F. Marijt, MD, PhD, J.H. Veelken, MD, PhD, I Jedema, PhD

Blood (2011) 118 (21): 1979.

https://doi.org/10.1182/blood.V118.21.1979.1979

Published: 2011

Journal Articles

Potent B Cell Leukemia-Reactive T Cells Present in Naive Donor T Cell Populations Can Be Isolated under GMP Conditions Using a Universal Stimulation and Isolation Procedure.

I. Jedema, J. Olde Wolbers, E. Steeneveld, A.-M. Rasmussen, W.M. Smit, R. Willemze, J.H. Frederik Falkenburg

Blood (2006) 108 (11): 3689.

https://doi.org/10.1182/blood.V108.11.3689.3689

Published: 2006

Journal Articles

Resistance of Quiescent Cells to T Cell Attack Determines Both the Efficacy and Specificity of Adoptive T Cell Therapy.

I. Jedema, C.A.M. van Bergen, M.G.D. Kester, R. Willemze, J.H. Frederik Falkenburg

Blood (2006) 108 (11): 3161.

https://doi.org/10.1182/blood.V108.11.3161.3161

Published: 2006

Journal Articles

Depletion of In-Vivo Activated Regulatory T Cells Followed by Synchronized Specific In-Vitro Activation Allows the Rapid Isolation of Leukemia-Reactive T Cells for Immunotherapy.

I. Jedema, E. Steeneveld, M. Hoogendoorn, R. Willemze, J.H.F. Falkenburg

Blood (2004) 104 (11): 297.

https://doi.org/10.1182/blood.V104.11.297.297

Published: 2004

Journal Articles

Primary Allogeneic T-Cell Responses Against In Vitro Modified Mantle Cell Lymphoma (MCL) Cells: Implications for Adoptive Immunotherapy after HLA-Matched Stem Cell Transplantation (SCT).

M. Hoogendoorn, MD, J. Olde Wolbers, W. M. Smit, MD PhD, I. Jedema, PhD, M. R. Schaafsma, MD PhD, R. M.Y. Barge, MD PhD, R. Willemze, MD PhD, J. H.F. Falkenburg, MD PhD

Blood (2004) 104 (11): 2118.

https://doi.org/10.1182/blood.V104.11.2118.2118

Published: 2004

NARROW

Purified CD4 T Lymphocyte Infusion Can Result in Graft-Versus-Leukemia Reactivity without Gvhd by Recognition of Broadly Expressed Minor Histocompatibility Antigens in HLA Class-II

Alemtuzumab Treatment Can Affect CD52 Positive As Well As CD52 Negative GPI-Deficient, Sezary Cells Allowing Long-Term Disease Control

In Vivo T Cell Depletion Using Rabbit Derived ATG Leads to An Increased EBV-PTLD Risk Due to An Induced Imbalance Between B and T Cell Recovery Which Is Not Seen After Horse Derived ATG or Alemtuzumab

Potent B Cell Leukemia-Reactive T Cells Present in Naive Donor T Cell Populations Can Be Isolated under GMP Conditions Using a Universal Stimulation and Isolation Procedure.

Resistance of Quiescent Cells to T Cell Attack Determines Both the Efficacy and Specificity of Adoptive T Cell Therapy.

Depletion of In-Vivo Activated Regulatory T Cells Followed by Synchronized Specific In-Vitro Activation Allows the Rapid Isolation of Leukemia-Reactive T Cells for Immunotherapy.

Primary Allogeneic T-Cell Responses Against In Vitro Modified Mantle Cell Lymphoma (MCL) Cells: Implications for Adoptive Immunotherapy after HLA-Matched Stem Cell Transplantation (SCT).

Email alerts

ASH Publications

American Society of Hematology

Purified CD4 T Lymphocyte Infusion Can Result in Graft-Versus-Leukemia Reactivity without Gvhd by Recognition of Broadly Expressed Minor Histocompatibility Antigens in HLA Class-II

Alemtuzumab Treatment Can Affect CD52 Positive As Well As CD52 Negative GPI-Deficient, Sezary Cells Allowing Long-Term Disease Control

In Vivo T Cell Depletion Using Rabbit Derived ATG Leads to An Increased EBV-PTLD Risk Due to An Induced Imbalance Between B and T Cell Recovery Which Is Not Seen After Horse Derived ATG or Alemtuzumab

Potent B Cell Leukemia-Reactive T Cells Present in Naive Donor T Cell Populations Can Be Isolated under GMP Conditions Using a Universal Stimulation and Isolation Procedure.

Resistance of Quiescent Cells to T Cell Attack Determines Both the Efficacy and Specificity of Adoptive T Cell Therapy.

Depletion of In-Vivo Activated Regulatory T Cells Followed by Synchronized Specific In-Vitro Activation Allows the Rapid Isolation of Leukemia-Reactive T Cells for Immunotherapy.

Primary Allogeneic T-Cell Responses Against In Vitro Modified Mantle Cell Lymphoma (MCL) Cells: Implications for Adoptive Immunotherapy after HLA-Matched Stem Cell Transplantation (SCT).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only